Faecal elastase 1 in chronic pancreatitis

Gut ◽  
1999 ◽  
Vol 44 (2) ◽  
pp. 290.3-290
Author(s):  
L GULLO
2012 ◽  
Vol 142 (5) ◽  
pp. S-462 ◽  
Author(s):  
Yazan Abdalla ◽  
Nimah Jamaluddin ◽  
Sean M. Burns ◽  
Samer Alkaade

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Mazen Shobassy ◽  
Nedaa Husainat ◽  
Abdalaziz Tabash ◽  
Kalpesh Patel ◽  
Hashem B. El-Serag ◽  
...  

Background and Aims. Fecal elastase-1 (FE-1) as a screening test for exocrine pancreatic insufficiency (EPI) is gaining popularity in clinical practice. The role of imaging in patients with FE-1-related suspicion of EPI remains unclear. The aim of this study was to characterize endoscopic ultrasound (EUS) findings for patients with low FE-1. Methods. A retrospective cross-sectional study was performed in 40 patients who had low FE-1 and underwent EUS to evaluate the pancreas. We obtained data on demographic and lifestyle factors, EUS findings, and histopathology results. We compared these variables between patients with FE‐1<100 mcg/g vs. 100-200 mcg/g. Results. Most patients (82.5%) established one or more new diagnoses from EUS. Diagnoses included: definitive chronic pancreatitis (n=29, 72.5%), fatty pancreas (n=9, 22.5%), and pancreatic solid mass or cyst (n=9, 22.5%). Half (n=4) of the solid or cystic lesions were neoplastic. All patients with a solid pancreatic mass also had concurrent chronic pancreatitis. There were no significant differences in EUS findings or demographic or lifestyle factors between groups with FE‐1<100 mcg/g vs. 100-200 mcg/g. Conclusion. Chronic pancreatitis is the most common EUS finding in patients with low FE-1 levels. EUS appears helpful in determining the cause of EPI in most patients with low FE-1 and may detect unsuspected pancreatic neoplasia.


1998 ◽  
Vol 114 ◽  
pp. A447 ◽  
Author(s):  
H.S. Choi ◽  
J.S. Ham ◽  
D.S. Han ◽  
J.H. Son ◽  
Y.C. Jun ◽  
...  

2021 ◽  
Vol 74 (10) ◽  
pp. 2541-2545
Author(s):  
Iryna V. Makhnitska ◽  
Liliya S. Babinets

The aim: To investigate the efficacy of Doctovit, a combination of dexpanthenol (provitamin B5) and methylmethionine (vitamin U), in the treatment of patients with chronić pancreatitis in combination with chronic erosive gastritis associated with H. pylori by studying the dynamics of stomach lining morphological changes. Materials and methods: Forty-five outpatients with CP and H.pylori CG were examined. The degree of excretory insufficiency of the pancreas was determined by the level of fecal α-elastase-1. At the beginning of the study and two months after the treatment has started, esophagogastroduodenoscopy + urease test for H. pylori + biopsy from 5 sites with histological examination has been performed. Results: It was found that a significant decrease in lymphohistiocytic infiltration of stomach lining, restoration of the structure of glands which have not undergone atrophy, increased focal hyperplasia (proliferation) of the glandular epithelium as signs of morphological restoration of the epithelium, reduction of epithelial dysplasia signs against the complete absence of positive dynamics of epithelial dysplasia in the group of patients receiving standard treatment of CP and CG, are clear and reliable signs of the effectiveness of vitamin Doctovit in complex therapy of CG associated with H.pylori, which indicate the feasibility of using the medicine to restore SL, which is the basis for effective carcinoprevention. Conclusions: The effectiveness of both treatment complexes in the correction of exocrine insufficiency of the pancreas by the dynamics of fecal α-elastase-1 was proved and which was statistically significantly higher when using the program with the inclusion of Doctovit: respectively 28.12% vs. 20.74% (p< 0.05). The total dynamics of morphological state improvement of stomach lining in the 1st group of patients was 0.9 points against 1.6 points in the 2nd group of patients, which was 17% and 32%, respectively (p <0.05), which activates clinical data on the effectiveness and feasibility of using a combination of dexpanthenol and methylmethionine according to the suggested scheme in the treatment of patients with chronic pancreatitis in comorbidity with H. pylori erosive CG.


2021 ◽  
Author(s):  
Sylvie Siminkovitch ◽  
Borislav Vladimirov, ◽  
Mila Kovacheva-Slavova ◽  
Plamen Getsov ◽  
Stoyanka Dineva

Pancreas ◽  
2002 ◽  
Vol 25 (1) ◽  
pp. e6-e9 ◽  
Author(s):  
Philip D. Hardt ◽  
Axel M. Marzeion ◽  
Henning Schnell-Kretschmer ◽  
Oliver Wüsten ◽  
Jens Nalop ◽  
...  

Pancreas ◽  
1996 ◽  
Vol 13 (3) ◽  
pp. 226-230 ◽  
Author(s):  
Stephen T. Amann ◽  
Michelle Bishop ◽  
Cheryl Curington ◽  
P. P. Toskes

Pancreatology ◽  
2003 ◽  
Vol 3 (5) ◽  
pp. 389-394 ◽  
Author(s):  
C. Gredal ◽  
L.G. Madsen ◽  
S. Larsen

Sign in / Sign up

Export Citation Format

Share Document